Gilead Licenses Novel Immunotherapy From Jounce

 
• By Joseph Haas
  
Brainstorming Group of people Working Concept. Business team brainstorming. Marketing plan researching. Paperwork on the table, laptop and mobile phone.
With its deal with Jounce, Gilead continues to pick up new IO partners
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business